Fast Track Group FTRK 深 滬
等待開盤 10-03 09:30:00 美东时间
0.5785
-0.021
-3.55%
華盛通- 最 高0.5998
- 今 開0.5818
- 成交量 10.57万股
- 最 低 0.545
- 昨 收 0.5998
- 總市值 1261.85万
- 52周最高 9.69
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 0.3898
- 委 比 -75.96%
- 總股本 2181.25万
- 歷史最高 9.69
- 量 比 0.73
- 振 幅 9.14%
- 歷史最低 0.3898
- 每 手 1
- 風險率 1.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
SAN DIEGO, Sept. 29, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-29 20:30
NRx Pharmaceuticals Re-Files Its Abbreviated New Drug Application With FDA For KETAFREE
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the re-filing of its Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for KETAFREE™, its preservative-free IV ketamine formulation, for use in all existing approved indications.
09-29 20:22
12 Communication Services Stocks Moving In Friday's Pre-Market Session
Gainers Harrison Global Holdings (NASDAQ: BLMZ) stock moved upwards by 20.8% to $0.22 during Friday's pre-market session. The market value of their outstanding shares is at $2.5 million.
09-26 20:10
MediciNova Completes Patient Enrollment In Phase 2/3 Clinical Trial, COMBAT-ALS For Treatment Of Amyotrophic Lateral Sclerosis
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient
09-22 20:09
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,...
09-18 21:10
Greenwich LifeSciences expands breast cancer trial to Ireland
Greenwich LifeSciences (NASDAQ:GLSI) said it has expanded its Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, to Ireland. The company's applicat...
09-18 18:25
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Corbus Pharmaceuticals Receives FDA Fast Track for CRB-701
An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On Se...
09-16 21:21
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
FDA Grants Teva Pharmaceutical's Emrusolmin Fast Track Designation For Multiple System Atrophy
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options
09-09 20:31
